Business Context and Reporting Period
This Form 8-K filing by SMI Products, Inc. (not Capricor Therapeutics, Inc.) covers events occurring on August 11, 2006, with a report date of August 14, 2006. The filing details a change of control, a fundamental shift in business strategy, and significant corporate governance changes.
Key Financial Metrics and Transactions
- Debt Restructuring: The Company amended and restated loan agreements with certain stockholders totaling approximately $89,316.32 in principal. These were converted into convertible promissory notes bearing 2% annual interest, payable on demand.
- Equity Transaction: Fountainhead Capital Partners, Ltd. (the "Purchaser") acquired 5,551,000 shares of common stock and the aforementioned notes for an aggregate purchase price of $637,500, plus the amount of cash or cash equivalents on the Company's balance sheet at closing.
- Ownership Structure: Post-transaction, the Purchaser owns approximately 73.5% of the Company's issued and outstanding capital stock on a fully-diluted basis.
- Liquidity: The filing does not provide specific values for the Company's cash balance at the time of closing, only that it was included in the purchase price calculation.
Material Changes Versus Prior Period
- Change of Control: Control of the Company shifted from James Charuk (who held 66.5% prior to the transaction) to Fountainhead Capital Partners, Ltd.
- Business Plan Pivot: The Company ceased its previous business of providing consulting services. The new business plan is to explore potential targets for a business combination via asset purchase, share exchange, or merger.
- Management Turnover: James Charuk resigned as the sole director, President, Treasurer, and Secretary. Geoffrey Alison was appointed to all these positions effective August 11, 2006.
Outlook, Risks, and Management Commentary
- Future Operations: The Company has no specific plans for acquisitions, mergers, or asset sales at this time beyond the general intent to seek a business combination.
- Management Commitment: The newly appointed President and Director, Geoffrey Alison, expects to spend approximately five hours per month on the Company's affairs.
- Compensation: No compensation arrangements have been entered into with the newly appointed officer or director.
- Risks: The Company is now a shell company seeking a target, which carries inherent risks regarding the ability to secure a viable business combination.
Investor Verification Checklist
- Verify the exact amount of cash and cash equivalents included in the $637,500 purchase price.
- Confirm the conversion terms and valuation of the $89,316.32 in convertible notes.
- Review the background and track record of Geoffrey Alison and Fountainhead Capital Partners, Ltd. regarding their ability to execute a business combination.
- Check for any undisclosed liabilities or contingent obligations not mentioned in the loan agreements.
- Monitor future filings for the identification of a specific acquisition target.